Obatoclax Mesylate (GX15-070)

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Price Stock Quantity  
USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Obatoclax Mesylate (GX15-070) Chemical Structure

Obatoclax Mesylate (GX15-070) Chemical Structure
Molecular Weight: 413.49

Validation & Quality Control

Customer Product Validation(9)

Quality Control & MSDS

Related Compound Libraries

Obatoclax Mesylate (GX15-070) is available in the following compound libraries:

Bcl-2 Inhibitors with Unique Features

  • Pan Bcl-2 Inhibitor

    ABT-737 Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

  • Most Potent Bcl-2 Inhibitor

    ABT-263 (Navitoclax) Bcl-xL, Ki≤ 0.5 nM; Bcl-2, Ki≤ 1 nM; Bcl-w, Ki≤ 1 nM.

  • Newest Bcl-2 Family Activator

    BAM7 Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.

  • Classic Bcl-2 Inhibitor

    ABT-737 BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Product Information

  • Compare Bcl-2 Inhibitors
    Compare Bcl-2 Products
  • Research Area

Product Description

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Targets Bcl-2 [1]
(Cell-free assay)
IC50 0.22 μM(Ki)
In vitro Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
KARPAS-45NEnyO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfvNmRKSzVyPUCuNFAxODNzNzFOwG0>NXvKbVdsW0GQR1XS
SK-MEL-30NGfQXnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLwZohDUUN3ME2wMlAxODN3NTFOwG0>NEjzOoNUSU6JRWK=
NALM-6MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX3yNoJ[UUN3ME2wMlAxODN3NjFOwG0>M1rlUHNCVkeHUh?=
KYSE-450NYm1SnRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1nJN2lEPTB;MD6wNFA1PjlizszNNWTkPWtMW0GQR1XS
BHYNYC1d2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEKwb4RKSzVyPUCuNFAxPjBzIN88US=>MYnTRW5ITVJ?
GR-STMk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4[zPGlEPTB;MD6wNFA3PDhizszNM{LFOnNCVkeHUh?=
786-0M1LLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXrmS4t{UUN3ME2wMlAxODd5NjFOwG0>NIW0TIRUSU6JRWK=
C-33-ANGLW[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwMECwPFQ5KM7:TR?=NVnpZlA4W0GQR1XS
BHT-101M4TIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;Kbm5OUUN3ME2wMlAxOTB4IN88US=>MWHTRW5ITVJ?
EB2NXXXS4R2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\JR5ZKSzVyPUCuNFAyOThizszNNUjKeVRUW0GQR1XS
G-361NW[ySZBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzqN5RKSzVyPUCuNFAyOjRizszNMonzV2FPT0WU
KE-37Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwMECxNlgh|ryPMV3TRW5ITVJ?
MHH-PREB-1NIH0dmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{W4NWlEPTB;MD6wNFE1KM7:TR?=MnrwV2FPT0WU
MCF7NWDJemRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHfYXWZKSzVyPUCuNFAyPTlizszNNVfYRWd3W0GQR1XS
LOUCYNVqxNZlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PI[mlEPTB;MD6wNFE4PSEQvF2=NWraXIlGW0GQR1XS
EW-7NUTHNXdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTBwMECxO|Uh|ryPMWTTRW5ITVJ?
KYSE-510M{PIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1vWcGlEPTB;MD6wNFI{OyEQvF2=MX3TRW5ITVJ?
SK-MEL-3M{D2emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTuVnlKSzVyPUCuNFAzPjRizszNNH3ZOplUSU6JRWK=
HAL-01NUjOeZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTBwMECyPVch|ryPMljLV2FPT0WU
HCC2998MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwMECzN|Uh|ryPNEPLSo5USU6JRWK=
A375NIjuc45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NW\HfGVvUUN3ME2wMlAxOzVizszNNX3URm1ZW0GQR1XS
MZ7-melM3KwOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV3JR|UxRTBwMECzPVkh|ryPM3jycnNCVkeHUh?=
SH-4MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTBwMEC0NVch|ryPNYmzbWhFW0GQR1XS
HT-144NWSwWIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrsOJVvUUN3ME2wMlAxPDNizszNMomwV2FPT0WU
KYSE-140MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWno[XJSUUN3ME2wMlAxPDN3IN88US=>M2XWZ3NCVkeHUh?=
PSN1M3fTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXm2N2RkUUN3ME2wMlAxPDZ5IN88US=>NHTBfYRUSU6JRWK=
COLO-679NEXFOmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2DzdWlEPTB;MD6wNFQ6QCEQvF2=NULSTZBzW0GQR1XS
SW620MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3uydWlEPTB;MD6wNFUyOSEQvF2=M3f2UXNCVkeHUh?=
HGC-27M{HINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLERY9KSzVyPUCuNFA2OjRizszNMnT1V2FPT0WU
IGROV-1NYjrbnBQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7wTWM2OD1yLkCwOkDPxE1?MVzTRW5ITVJ?
IGR-1NXS0OVNkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mk\pTWM2OD1yLkCwOlAyKM7:TR?=MV;TRW5ITVJ?
EW-1M4S5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTBwMEC2OVEh|ryPM4PmbnNCVkeHUh?=
769-PMni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7LfplKSzVyPUCuNFA3PzhizszNNVfEOHpsW0GQR1XS
HNNW\sVmhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;UTWM2OD1yLkCwOlc6KM7:TR?=NWH0[XRjW0GQR1XS
SIG-M5MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnrVTWM2OD1yLkCwO|Eh|ryPMV\TRW5ITVJ?
IST-MEL1NX65PYdFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn3tTWM2OD1yLkCwPFE5KM7:TR?=MnnYV2FPT0WU
ST486M3XI[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2fwXWlEPTB;MD6wNFgzPSEQvF2=Mli3V2FPT0WU
ES7M1PP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVT2NG96UUN3ME2wMlAxQDR4IN88US=>Mmj3V2FPT0WU
GAKMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXXMWmQ6UUN3ME2wMlAxQDR6IN88US=>NVXsdWc3W0GQR1XS
BB30-HNCNX;TflhWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\EWGlEPTB;MD6wNFg2QCEQvF2=M{SxU3NCVkeHUh?=
IPC-298MlfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PMfmlEPTB;MD6wNFkzPyEQvF2=MlG2V2FPT0WU
NKM-1NFjnZ2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXy4cG9XUUN3ME2wMlAxQTd{IN88US=>MX;TRW5ITVJ?
RKOMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7XTm94UUN3ME2wMlAyODR2IN88US=>NHXsfmpUSU6JRWK=
ACNM4PneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGXDTmZKSzVyPUCuNFEyOzFizszNM2nTSHNCVkeHUh?=
SW1417NV7Gdml1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3z3V2lEPTB;MD6wNVIzPSEQvF2=MVHTRW5ITVJ?
SRM135Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEm2enhKSzVyPUCuNFEzOzVizszNM1HNbXNCVkeHUh?=
SNG-MNX7GXGpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWG3eGNTUUN3ME2wMlAyOzF5IN88US=>M4HYPHNCVkeHUh?=
CAL-12TMnTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLpTWM2OD1yLkCxN|Q3KM7:TR?=M1PaeHNCVkeHUh?=
HSC-3NHrUUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLTeZU{UUN3ME2wMlAyOzV3IN88US=>M1\zPXNCVkeHUh?=
DOHH-2MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XSUGlEPTB;MD6wNVQyOiEQvF2=Mm[xV2FPT0WU
NB69M{TYOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fYNGlEPTB;MD6wNVU3PSEQvF2=MmDvV2FPT0WU
LC-2-adMl7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{O1dGlEPTB;MD6wNVU5OSEQvF2=M3nNO3NCVkeHUh?=
RVH-421NVrMSVlGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUHFR3BGUUN3ME2wMlAyPjd2IN88US=>MULTRW5ITVJ?
TGWNEXsfWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3q0V2lEPTB;MD6wNVc{QSEQvF2=M3ewd3NCVkeHUh?=
HCC1569MlLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVnJR|UxRTBwMEG3PVch|ryPM4qxOnNCVkeHUh?=
CAL-85-1MnjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2i1bWlEPTB;MD6wNVg{OiEQvF2=MV\TRW5ITVJ?
RPMI-8402NGruNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXWTWM2OD1yLkCxPFU5KM7:TR?=NHrGXI9USU6JRWK=
THP-1M2\s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmHSTWM2OD1yLkCxPVk5KM7:TR?=M1nabHNCVkeHUh?=
ONS-76NHXvb2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPXVoFKSzVyPUCuNFIxOzZizszNNULCbHZkW0GQR1XS
A2780M{\ITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXzJR|UxRTBwMEKwO|kh|ryPM2PBS3NCVkeHUh?=
RPMI-2650MnvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NELvZZFKSzVyPUCuNFIzQTZizszNNW[wOpNYW0GQR1XS
MEL-HOM4Lw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWfCTlBkUUN3ME2wMlAzOzR6IN88US=>MnniV2FPT0WU
MC-CARMkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3e3SGlEPTB;MD6wNlM2PiEQvF2=MkLtV2FPT0WU
HSC-2M2DtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mmj2TWM2OD1yLkCyOFY3KM7:TR?=M4[wZnNCVkeHUh?=
MEL-JUSONIHGWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{jycWlEPTB;MD6wNlQ4OyEQvF2=MnPTV2FPT0WU
CAL-62NX;4eoJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFL1WGlKSzVyPUCuNFI3ODJizszNNEHVNI1USU6JRWK=
DMS-273Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3vRc2lEPTB;MD6wNlg1PyEQvF2=M{HsUXNCVkeHUh?=
S-117MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGnFN3pKSzVyPUCuNFI6ODZizszNM{K1XHNCVkeHUh?=
SUP-T1NFfGW2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUnJR|UxRTBwMEK5OFkh|ryPNW[y[nNEW0GQR1XS
MZ2-MELMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mlf6TWM2OD1yLkCyPVU6KM7:TR?=MYPTRW5ITVJ?
KYSE-270MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoDSTWM2OD1yLkCyPVc3KM7:TR?=MlHBV2FPT0WU
CMKMUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPRTWM2OD1yLkCzNFI{KM7:TR?=M1jVTXNCVkeHUh?=
8505CMmn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH34bXhKSzVyPUCuNFMxPCEQvF2=MVrTRW5ITVJ?
NUGC-3NEnycXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\T[2lEPTB;MD6wN|A1QCEQvF2=NVL3b5pVW0GQR1XS
A101DMmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jJc2lEPTB;MD6wN|A2PSEQvF2=MkXPV2FPT0WU
G-401NYHXPVh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLqTWM2OD1yLkCzNFk{KM7:TR?=NUPkT|NjW0GQR1XS
OVCAR-8NFfPSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYHNb2hMUUN3ME2wMlA{OTB5IN88US=>M4ThNHNCVkeHUh?=
IMR-5NI\WcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHTTWM2OD1yLkCzNlQ1KM7:TR?=MWHTRW5ITVJ?
DoTc2-4510MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NULwUJk2UUN3ME2wMlA{Ozl|IN88US=>MUjTRW5ITVJ?
HOSMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzj[lhMUUN3ME2wMlA{PDd|IN88US=>NVnJOpR{W0GQR1XS
HEC-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX7ROFNCUUN3ME2wMlA{PjhizszNMUfTRW5ITVJ?
SW756MlmwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7rfVFMUUN3ME2wMlA{QDJzIN88US=>MVzTRW5ITVJ?
NCI-H64M1POe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmjhTWM2OD1yLkCzPFQzKM7:TR?=M2fFS3NCVkeHUh?=
EW-16MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVjJR|UxRTBwMEO5NFkh|ryPNEC2fGxUSU6JRWK=
CAL-51M{DpUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\mOFFpUUN3ME2wMlA1ODB3IN88US=>M1TONXNCVkeHUh?=
KYSE-150MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTBwMESwNVEh|ryPNIHI[2NUSU6JRWK=
SW1710MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEezXXVKSzVyPUCuNFQxOThizszNNUDDNnlsW0GQR1XS
HuP-T4M2T3dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFq0b2tKSzVyPUCuNFQyOThizszNNHi2e3JUSU6JRWK=
LB373-MEL-DM4DFO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4PNcmlEPTB;MD6wOFI{OiEQvF2=NILheYVUSU6JRWK=
EW-13MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWLTZWJsUUN3ME2wMlA1PDB4IN88US=>MYrTRW5ITVJ?
HT-29MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLlTWM2OD1yLkC0OFkh|ryPMnrxV2FPT0WU
SCC-25MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHCe4JDUUN3ME2wMlA1PDl2IN88US=>MoTOV2FPT0WU
REHNIDrTGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwMES2N|Uh|ryPNF3PXWtUSU6JRWK=
L-363M3XTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmLSTWM2OD1yLkC0Olc6KM7:TR?=NXT1cnRFW0GQR1XS
NCI-H1770MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LkR2lEPTB;MD6wOFY6PyEQvF2=MofrV2FPT0WU
CHL-1Mn2wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3jtcGlEPTB;MD6wOFg2PyEQvF2=NYS0W3d7W0GQR1XS
ES1NXvBbHQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnkOldKSzVyPUCuNFQ5QDVizszNMX7TRW5ITVJ?
SCC-15MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnPZTWM2OD1yLkC0PVAzKM7:TR?=MkDIV2FPT0WU
MRK-nu-1NFnt[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq1TWM2OD1yLkC0PVM3KM7:TR?=MlTYV2FPT0WU
PF-382MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{D1[mlEPTB;MD6wOFk{QSEQvF2=NIDiWoNUSU6JRWK=
COLO-680NM3HlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{nXcGlEPTB;MD6wOVA1PyEQvF2=M1yx[nNCVkeHUh?=
LK-2MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4[4[mlEPTB;MD6wOVA3OyEQvF2=NGH6NZlUSU6JRWK=
NCI-H2342NHrseHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWrL[WNQUUN3ME2wMlA2OTF5IN88US=>MY\TRW5ITVJ?
HMV-IINWq5SnJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTBwMEWyN|kh|ryPNFPmVo1USU6JRWK=
PC-14NH;NTXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jWXmlEPTB;MD6wOVI2OiEQvF2=NHnCc5VUSU6JRWK=
COLO-320-HSRMnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2PxbWlEPTB;MD6wOVI5QSEQvF2=NXLJXVdwW0GQR1XS
697NFLXdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:4XWVKSzVyPUCuNFU{OjNizszNMn;WV2FPT0WU
NEC8MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DZeGlEPTB;MD6wOVU6KM7:TR?=MnPzV2FPT0WU
LCLC-97TM1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELvU|NKSzVyPUCuNFU2QTRizszNM4DEe3NCVkeHUh?=
DaoyNUPCOJQ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoryTWM2OD1yLkC1OlE3KM7:TR?=M4POfHNCVkeHUh?=
ETK-1M1XEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTBwMEW2O|Ih|ryPMUfTRW5ITVJ?
A388MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXnCOHhjUUN3ME2wMlA2Pjl3IN88US=>M1v1[3NCVkeHUh?=
COLO-205MlnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{[xeGlEPTB;MD6wOVcyPiEQvF2=MnfUV2FPT0WU
SK-PN-DWMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkLUTWM2OD1yLkC1O|I6KM7:TR?=M4XOT3NCVkeHUh?=
SF268NVraUHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLaTWM2OD1yLkC1O|U3KM7:TR?=NWPVToE6W0GQR1XS
OCI-AML2NVLZRYtHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1;scmlEPTB;MD6wOVc4PyEQvF2=NVT6O453W0GQR1XS
GAMGNETYTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DqdGlEPTB;MD6wOVgh|ryPMWnTRW5ITVJ?
BCPAPNXnXend6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjwTWM2OD1yLkC1PFkzKM7:TR?=Ml3BV2FPT0WU
BC-1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYrO[Is4UUN3ME2wMlA3ODJ{IN88US=>NHfXWG5USU6JRWK=
IA-LMM1rsfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4O1dmlEPTB;MD6wOlA2OyEQvF2=NYPmVoRNW0GQR1XS
NCI-H1299NGKyV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3;qcWlEPTB;MD6wOlE{KM7:TR?=MlvMV2FPT0WU
COR-L23NHPibYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;GVJZKSzVyPUCuNFYyOzRizszNNIDDeIZUSU6JRWK=
KYSE-180NWrmfIFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWLJR|UxRTBwME[xOFIh|ryPNFS1RYZUSU6JRWK=
LOXIMVIMonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jlXmlEPTB;MD6wOlE5QCEQvF2=NYfFbpRIW0GQR1XS
BL-41MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvC[ItIUUN3ME2wMlA3OjF7IN88US=>Mn63V2FPT0WU
BL-70MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHi3RVFKSzVyPUCuNFY{ODJizszNMVrTRW5ITVJ?
NOS-1MnXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\RTWM2OD1yLkC2OFEyKM7:TR?=NV3zSYFkW0GQR1XS
NB13MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHBblBDUUN3ME2wMlA3PDJzIN88US=>MXnTRW5ITVJ?
CAL-27MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfWTWM2OD1yLkC2OFY1KM7:TR?=NYTadlI6W0GQR1XS
CA46MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MneyTWM2OD1yLkC2OVM4KM7:TR?=M{\McXNCVkeHUh?=
SW962NGT0epFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2q4[2lEPTB;MD6wOlU3QSEQvF2=MUHTRW5ITVJ?
NCI-H226M4LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTBwME[2N|Ih|ryPMYTTRW5ITVJ?
KYSE-70NHuzepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXLWUYdDUUN3ME2wMlA3QTR3IN88US=>NWLaV|MyW0GQR1XS
DaudiMojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkHoTWM2OD1yLkC3NFgyKM7:TR?=M2DFfnNCVkeHUh?=
SW626MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XRfmlEPTB;MD6wO|IxPCEQvF2=NITaN2lUSU6JRWK=
ESS-1M4XLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTBwMEeyOFYh|ryPNHrVZ4xUSU6JRWK=
YTNHvofZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHrMVYRKSzVyPUCuNFc{PDVizszNNV;QeodmW0GQR1XS
P12-ICHIKAWANGqzRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHPO[pdKSzVyPUCuNFc{PDlizszNMoTOV2FPT0WU
BxPC-3NWWyS2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFntPVFKSzVyPUCuNFc1PThizszNNWnwVJdNW0GQR1XS
CTV-1NFnlco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFX5[ZhKSzVyPUCuNFc2OTdizszNNF3jW3VUSU6JRWK=
MLMAMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NESyOZRKSzVyPUCuNFc2OzRizszNMWnTRW5ITVJ?
WSU-NHLM4LnWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1LzemlEPTB;MD6wO|U2PCEQvF2=MUHTRW5ITVJ?
CTB-1NFnG[mpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUL5cVRGUUN3ME2wMlA4PTh6IN88US=>NHrL[|hUSU6JRWK=
MMAC-SFMkTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojYTWM2OD1yLkC3OlY5KM7:TR?=M1uxSXNCVkeHUh?=
8-MG-BAMlPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MknkTWM2OD1yLkC3PFAyKM7:TR?=MXTTRW5ITVJ?
NCI-H358MkDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwMEe4O|kh|ryPMWLTRW5ITVJ?
BFTC-905MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDpNGd5UUN3ME2wMlA4QTB7IN88US=>M4rYZnNCVkeHUh?=
NCI-H727MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUXFTWt2UUN3ME2wMlA5ODV|IN88US=>NYnYfZozW0GQR1XS
CHP-212M4\xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWqycItoUUN3ME2wMlA5ODl3IN88US=>NYfoUnZ7W0GQR1XS
HOP-62MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW[2PFhuUUN3ME2wMlA5OjR3IN88US=>M{nLcXNCVkeHUh?=
CESSNGG3ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjQZ417UUN3ME2wMlA5OjZ7IN88US=>NHvv[YxUSU6JRWK=
HuCCT1M3n6Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXaR2VkUUN3ME2wMlA5OzN|IN88US=>NXjO[mFtW0GQR1XS
DELNFnDbYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnFT49mUUN3ME2wMlA5OzR5IN88US=>M2rGVHNCVkeHUh?=
5637NFzlb|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFn6S2NKSzVyPUCuNFg{PjdizszNNG[zVHJUSU6JRWK=
RS4-11M2PkOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV7JR|UxRTBwMEi0PVch|ryPNIDvdG1USU6JRWK=
KURAMOCHINUmwPYZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTBwMEi1NFkh|ryPM3LLfnNCVkeHUh?=
A427Mm\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlrxTWM2OD1yLkC4OVEzKM7:TR?=MnXkV2FPT0WU
A3-KAWM2W3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zyZWlEPTB;MD6wPFU3PiEQvF2=M1\wU3NCVkeHUh?=
LS-123M1\OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXLTWM2OD1yLkC4O|E6KM7:TR?=NEHyOJhUSU6JRWK=
LoVoMn\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXzJR|UxRTBwMEi3NkDPxE1?MlXKV2FPT0WU
PA-1Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TPbGlEPTB;MD6wPFc3QSEQvF2=NGr5fpdUSU6JRWK=
CP50-MEL-BM2HkeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkCxTWM2OD1yLkC4O|k{KM7:TR?=MVrTRW5ITVJ?
A431MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjoTVZKSzVyPUCuNFg5ODFizszNM3K1SXNCVkeHUh?=
HCT-116MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDiXVNKSzVyPUCuNFg5ODJizszNMkjMV2FPT0WU
A4-FukMnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fXbmlEPTB;MD6wPFk1PyEQvF2=NHmzeHNUSU6JRWK=
RPMI-6666M{G4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHINVBQUUN3ME2wMlA5QTZ5IN88US=>M2HIN3NCVkeHUh?=
Calu-6NIexPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWn0SWhKUUN3ME2wMlA6ODJ7IN88US=>NXvkUYh1W0GQR1XS
KMOE-2MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O2N2lEPTB;MD6wPVA{QSEQvF2=NHvWRXRUSU6JRWK=
A704NVSyPZF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfJ[nJKSzVyPUCuNFkyPSEQvF2=M{HD[nNCVkeHUh?=
HO-1-N-1NGO2SVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrZV2tyUUN3ME2wMlA6OjR7IN88US=>NIrkNnNUSU6JRWK=
NCI-H2122MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETyfmlKSzVyPUCuNFk{PzhizszNMoDIV2FPT0WU
U-698-MMl3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVXI[o9UUUN3ME2wMlA6PDB7IN88US=>Mne3V2FPT0WU
IST-SL2Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUGw[JJDUUN3ME2wMlA6PDZ6IN88US=>NUPLZYNlW0GQR1XS
TE-10MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGTESY1KSzVyPUCuNFk2QDRizszNNEjKS2pUSU6JRWK=
PANC-03-27MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrFXIRlUUN3ME2wMlA6PjdzIN88US=>NX;GcHNkW0GQR1XS
KYSE-410M3TVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{iz[WlEPTB;MD6wPVc6PyEQvF2=MYjTRW5ITVJ?
TE-8NX76RpVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTBwMEm4PFUh|ryPMU\TRW5ITVJ?
MN-60Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTBwMEm4PVch|ryPM{m1cHNCVkeHUh?=
NCI-H460MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnywTWM2OD1yLkGwNFkh|ryPMVjTRW5ITVJ?
LB771-HNCM3;heGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljiTWM2OD1yLkGwNlU2KM7:TR?=M4DteXNCVkeHUh?=
ES4MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHRTWM2OD1yLkGwNlY1KM7:TR?=MXvTRW5ITVJ?
HUTU-80NHfDVYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrF[Y1IUUN3ME2wMlExOzZ3IN88US=>NGjwWldUSU6JRWK=
647-VM176emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3u5bWlEPTB;MD6xNFQxQCEQvF2=NX60OXJ3W0GQR1XS
HTC-C3M{\3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PtbGlEPTB;MD6xNFQ{OiEQvF2=MoG2V2FPT0WU
NTERA-S-cl-D1MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3z5c2lEPTB;MD6xNFQ1QCEQvF2=MlL4V2FPT0WU
A2058M3y2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mnz2TWM2OD1yLkGwOlU2KM7:TR?=NIPV[ItUSU6JRWK=
MZ1-PCNF70cFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXTTWM2OD1yLkGwPFMh|ryPMlvFV2FPT0WU
J82NXPDO2lMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nhSWlEPTB;MD6xNFg5PCEQvF2=MmTGV2FPT0WU
ARH-77MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWnJR|UxRTBwMUGg{txONGLrZYlUSU6JRWK=
Ca9-22M{PlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;XSlN1UUN3ME2wMlEyOTJ6IN88US=>MljpV2FPT0WU
NCI-H1648NITMS2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTBwMUGyPFYh|ryPMUDTRW5ITVJ?
MC116M3PWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnTKTWM2OD1yLkGxN|M4KM7:TR?=MVPTRW5ITVJ?
EoL-1-cellNVzs[VBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPpc4szUUN3ME2wMlEyPDZ5IN88US=>M3jzOnNCVkeHUh?=
PANC-10-05NVy3WpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXLke4x2UUN3ME2wMlEyPDlzIN88US=>Mn\kV2FPT0WU
SF539MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYq5VY9VUUN3ME2wMlEyPjF4IN88US=>NFvpeHFUSU6JRWK=
ES8NV[5R3NCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3TWPWlEPTB;MD6xNVY{OyEQvF2=MXjTRW5ITVJ?
NCI-H810MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{POdmlEPTB;MD6xNVY3PCEQvF2=MVrTRW5ITVJ?
J-RT3-T3-5NXLCdYoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MU\JR|UxRTBwMUG3OUDPxE1?MYnTRW5ITVJ?
NYMnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTBwMUG4NVch|ryPNG\kdWVUSU6JRWK=
NCI-SNU-1M1zlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYexXWwyUUN3ME2wMlEzOTR6IN88US=>NF;3ZotUSU6JRWK=
EFM-19MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnkS41KSzVyPUCuNVI{PzRizszNMofiV2FPT0WU
HCC1806MmPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlXXTWM2OD1yLkGyN|g{KM7:TR?=MoTtV2FPT0WU
HCE-TMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIDzZZJKSzVyPUCuNVI2OzFizszNNYjIWIdoW0GQR1XS
HT-1376MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7NTWM2OD1yLkGyOlY5KM7:TR?=NHfwXVVUSU6JRWK=
BE-13NUTqcVRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjUSnBmUUN3ME2wMlEzQDZ4IN88US=>NY[3fm4yW0GQR1XS
NCI-H520NE\oSXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIWwWHhKSzVyPUCuNVI5PjdizszNNF\UU5hUSU6JRWK=
SK-MES-1NWf5WWhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFjtU49KSzVyPUCuNVI6OTNizszNNVTEfpp5W0GQR1XS
SNU-423NH6zNZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlfTTWM2OD1yLkGyPVE1KM7:TR?=NGPvfnZUSU6JRWK=
Ramos-2G6-4C10MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2Ly[WlEPTB;MD6xNlkyPiEQvF2=MVnTRW5ITVJ?
EW-18NHXZT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHS0XIxKSzVyPUCuNVMxOjZizszNM4q1dXNCVkeHUh?=
NCI-H2087M1r0[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTBwMUOwNlch|ryPMn;hV2FPT0WU
COLO-792MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTBwMUOxOlUh|ryPMXjTRW5ITVJ?
QIMR-WILNUHuW2dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEnZO3VKSzVyPUCuNVMzOjNizszNNWLLVYc6W0GQR1XS
ACHNM2jQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7oN5lpUUN3ME2wMlE{OjR5IN88US=>NF3qV2dUSU6JRWK=
RPMI-8866MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHK0[3VKSzVyPUCuNVMzPjFizszNMWPTRW5ITVJ?
SK-LU-1Ml\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4i5UGlEPTB;MD6xN|Q1QSEQvF2=NVfV[pY{W0GQR1XS
SK-UT-1NWLldVl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHHSNWZKSzVyPUCuNVM3OjhizszNNVnxc4ZoW0GQR1XS
MFE-296MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVzJR|UxRTBwMUO4OlQh|ryPNVS3fldFW0GQR1XS
RDNULCOotWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfQZmNlUUN3ME2wMlE{QTl5IN88US=>MU\TRW5ITVJ?
LS-411NMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33tcmlEPTB;MD6xOFI6PSEQvF2=NUnqRmtWW0GQR1XS
NCI-H747MlXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWXmfml3UUN3ME2wMlE1OyEQvF2=M1fFU3NCVkeHUh?=
ES6NHzUToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmPUTWM2OD1yLkG0N|Yh|ryPM2O5RnNCVkeHUh?=
TE-1NIDOe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7WTWM2OD1yLkG0OFA4KM7:TR?=MUjTRW5ITVJ?
SJSA-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3KxV2lEPTB;MD6xOFcxPyEQvF2=MnS4V2FPT0WU
NCI-H1355NHzsZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MW\JR|UxRTBwMUWyPVMh|ryPM16xbHNCVkeHUh?=
HELM{j0U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mkj5TWM2OD1yLkG1OFQ4KM7:TR?=NGn0dGpUSU6JRWK=
639-VNX;IOmlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPTV2JKSzVyPUCuNVU2QTZizszNNGfqOlJUSU6JRWK=
AN3-CANFjQZWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwMUW2N|kh|ryPNED4d4hUSU6JRWK=
SK-MEL-2NV;aWIhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWTIUWxxUUN3ME2wMlE2PjZ6IN88US=>NVHEWIQ6W0GQR1XS
SW872MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYSy[lcyUUN3ME2wMlE3ODR{IN88US=>NEfKcYNUSU6JRWK=
DU-4475NUPie5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfrc5doUUN3ME2wMlE3OTZ{IN88US=>MVTTRW5ITVJ?
YKG-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYPWS3JtUUN3ME2wMlE3Ojd|IN88US=>MVTTRW5ITVJ?
GT3TKBMlXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NU\jOllXUUN3ME2wMlE3Ojh|IN88US=>MnLCV2FPT0WU
GB-1M4HIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofTTWM2OD1yLkG2OFI1KM7:TR?=MVrTRW5ITVJ?
KARPAS-422M2HDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXOXFJKSzVyPUCuNVY2PzRizszNNXf2dWdjW0GQR1XS
ATN-1M2rM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTBwMU[2OVYh|ryPMoiwV2FPT0WU
HLENYjGOWUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPNTWM2OD1yLkG2PFc4KM7:TR?=NFjnfVRUSU6JRWK=
D-542MGMoHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zkb2lEPTB;MD6xOlk5PiEQvF2=M2j0SnNCVkeHUh?=
EB-3NFeydY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3LtbWlEPTB;MD6xO|MyKM7:TR?=Mn7lV2FPT0WU
HCC1143NEjOUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3\kW2lEPTB;MD6xO|M6PiEQvF2=M2i0bnNCVkeHUh?=
DJM-1MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml\xTWM2OD1yLkG3OFUyKM7:TR?=M1jCWHNCVkeHUh?=
BT-474M3jzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTBwMUe0PFkh|ryPM4DKO3NCVkeHUh?=
BB65-RCCM{jN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTJeZl1UUN3ME2wMlE4PTR3IN88US=>MkjDV2FPT0WU
NCI-H292M2S2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXjPfZBMUUN3ME2wMlE4PjBzIN88US=>MlvCV2FPT0WU
MKN28NWnrcHF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrJTWM2OD1yLkG3OlU{KM7:TR?=MVrTRW5ITVJ?
TK10Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYDJR|UxRTBwMUe3NFIh|ryPM1vyNXNCVkeHUh?=
TYK-nuNH\CdpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonZTWM2OD1yLkG3PVQ6KM7:TR?=Ml3YV2FPT0WU
8305CNF\DO21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1rvWWlEPTB;MD6xO|k4OSEQvF2=NHr5OXJUSU6JRWK=
MV-4-11M4G2UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXnRnlmUUN3ME2wMlE4QTd5IN88US=>MkHIV2FPT0WU
NCI-H522NYfiSHRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYLJR|UxRTBwMUiwPVQh|ryPMoTGV2FPT0WU
Hs-578-TNXTibpQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTMTWM2OD1yLkG4NlkzKM7:TR?=NHf3b4NUSU6JRWK=
LCLC-103HM4r1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DaSGlEPTB;MD6xPFUzPyEQvF2=MmLqV2FPT0WU
MHH-ES-1MkLOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfpW41KSzVyPUCuNVg3OjlizszNMl3NV2FPT0WU
NCI-H441MnLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDEe212UUN3ME2wMlE6OTR6IN88US=>M3PZenNCVkeHUh?=
AM-38Mlj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoPmTWM2OD1yLkG5NlI2KM7:TR?=NHXscYtUSU6JRWK=
SW1783M1zPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rTUGlEPTB;MD6xPVMxPSEQvF2=MnHvV2FPT0WU
SK-HEP-1NWjiUWNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIPLcZdKSzVyPUCuNVk3OzdizszNNEe0[GFUSU6JRWK=
OAW-28NYrkUIRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWHJR|UxRTBwMkCxO|gh|ryPMXjTRW5ITVJ?
TE-15NWLwNHFRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXQ[2xYUUN3ME2wMlIxOjV{IN88US=>MUnTRW5ITVJ?
HCE-4MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzNRZkyUUN3ME2wMlIxOjh2IN88US=>NYrKTYZ5W0GQR1XS
JiyoyeP-2003NVjHR4hXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoPnTWM2OD1yLkKwN|M3KM7:TR?=NXH0Rok4W0GQR1XS
OVCAR-4MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUWx[Xp{UUN3ME2wMlIxPjJ6IN88US=>NIfWS2ZUSU6JRWK=
SNU-449NXTFd4VDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTBwMkC3PVch|ryPMVrTRW5ITVJ?
SBC-5MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moe2TWM2OD1yLkKxNlE2KM7:TR?=NEnTVVhUSU6JRWK=
T84M2\4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTBwMkGyOFgh|ryPNFu5U5ZUSU6JRWK=
LP-1NX:4fm9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLsNFBlUUN3ME2wMlIyOzB{IN88US=>MX\TRW5ITVJ?
MG-63MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PqN2lEPTB;MD6yNVM5OiEQvF2=M3zI[HNCVkeHUh?=
OAW-42M4DTRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnKwTWM2OD1yLkKxOFc5KM7:TR?=NXPUPVhDW0GQR1XS
L-540MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DwSWlEPTB;MD6yNVU6QCEQvF2=M4LqOHNCVkeHUh?=
RH-1MmDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn:xTWM2OD1yLkKyNlQzKM7:TR?=M33hPXNCVkeHUh?=
HCT-15NHLKSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUXJR|UxRTBwMkK0PFQh|ryPM1zZSXNCVkeHUh?=
OCUB-MMlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPEWHBKSzVyPUCuNlI1QDhizszNNW\wPXk2W0GQR1XS
GP5dM1\3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvkSXY1UUN3ME2wMlIzPTJ6IN88US=>MlfIV2FPT0WU
NCI-H2030NF7NNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3W5TmlEPTB;MD6yNlc{PCEQvF2=MUDTRW5ITVJ?
ML-2MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTBwMkK4PFkh|ryPMnHYV2FPT0WU
CAL-39NYL3dnB6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXOTWM2OD1yLkKyPVM3KM7:TR?=NUjic5dOW0GQR1XS
MIA-PaCa-2Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3nHbWlEPTB;MD6yN|I5PyEQvF2=MmLPV2FPT0WU
TE-9NHvMTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MorHTWM2OD1yLkKzN|Ih|ryPNYH3NY9yW0GQR1XS
LB2518-MELMlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwMkOzO|Ih|ryPMWHTRW5ITVJ?
DBNGj4XmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnKxTWM2OD1yLkKzOFM5KM7:TR?=M{L3d3NCVkeHUh?=
NCI-H596MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XRNWlEPTB;MD6yN|U4OSEQvF2=NFjEPJRUSU6JRWK=
SW1990MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTBwMkO5OFYh|ryPNF\QS5dUSU6JRWK=
P30-OHKNGPjbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkTMTWM2OD1yLkK0NFUh|ryPM4\5ZXNCVkeHUh?=
ALL-PONXrQfpVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVS5[lhbUUN3ME2wMlI1OTZ7IN88US=>M4rIe3NCVkeHUh?=
Saos-2M4O5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWi2RmhQUUN3ME2wMlI1PTdzIN88US=>NXW2c4FVW0GQR1XS
MFH-inoMmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFj0U4tKSzVyPUCuNlQ3QTJizszNMYPTRW5ITVJ?
OE33M1vWUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHfoeZhKSzVyPUCuNlUyOSEQvF2=NX3jdG93W0GQR1XS
Calu-3MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHVTWM2OD1yLkK1Nlk4KM7:TR?=NXznW|k6W0GQR1XS
HTMYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoG4TWM2OD1yLkK1OlIyKM7:TR?=NHnHUJhUSU6JRWK=
LXF-289NHLmTYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnf5TWM2OD1yLkK1PVg1KM7:TR?=NUf4SmVIW0GQR1XS
KGNMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYTJR|UxRTBwMk[wPFkh|ryPNGi3NIhUSU6JRWK=
NCI-H1417NGLiVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHzyd|FKSzVyPUCuNlY2OjRizszNNU\RNlE3W0GQR1XS
SF126NH\ZVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETpTIlKSzVyPUCuNlc{ODJizszNNFPRNVBUSU6JRWK=
SASNELSboFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3QS4VKSzVyPUCuNlc{ODhizszNMUDTRW5ITVJ?
22RV1MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\pTWM2OD1yLkK3N|c5KM7:TR?=NUP2d|ViW0GQR1XS
GI-1NITIVHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnPSWdkUUN3ME2wMlI4PDh5IN88US=>NFv0OYdUSU6JRWK=
ES3Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTBwMke3OlMh|ryPMV3TRW5ITVJ?
NB1MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXXzVIRjUUN3ME2wMlI4QDd4IN88US=>NFvqTVhUSU6JRWK=
NCI-H650MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTUTWM2OD1yLkK4N|AzKM7:TR?=MV;TRW5ITVJ?
IST-MES1NVzLdZpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWDJR|UxRTBwMki1OVQh|ryPMVvTRW5ITVJ?
UM-UC-3MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2TvXWlEPTB;MD6yPVE1KM7:TR?=MV;TRW5ITVJ?
CAL-120MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTBwMkm2N|Eh|ryPNGjiRVhUSU6JRWK=
UACC-62MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NY\TXIdRUUN3ME2wMlMxOjRzIN88US=>MYrTRW5ITVJ?
TE-11Mor2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTBwM{CyOFkh|ryPNVjvV|BVW0GQR1XS
MKN1MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHPFZmJKSzVyPUCuN|A{PiEQvF2=NYnufJhvW0GQR1XS
KS-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\jc4lOUUN3ME2wMlMxPTJ4IN88US=>MoGxV2FPT0WU
GCIYM3rhWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2DP[GlEPTB;MD6zNVAxOiEQvF2=MWPTRW5ITVJ?
OVCAR-5NVX4ZZhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXodY1HUUN3ME2wMlMyOTB4IN88US=>M{KxUHNCVkeHUh?=
U-266MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXW2d5I3UUN3ME2wMlMyOTR5IN88US=>M2LQeXNCVkeHUh?=
Calu-1MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3PqbmlEPTB;MD6zNVI5QSEQvF2=Mn[yV2FPT0WU
SK-LMS-1M4DaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDZXnNKSzVyPUCuN|E1OjlizszNMoXWV2FPT0WU
COLO-741NE\rV|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTBwM{G2NVQh|ryPMYDTRW5ITVJ?
RPMI-8226NWfV[ZBnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nxe2lEPTB;MD6zNVY1OSEQvF2=MmDCV2FPT0WU
KM12NVK0fWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PqdGlEPTB;MD6zNVg{KM7:TR?=MkDSV2FPT0WU
NMC-G1M3PobWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYjJR|UxRTBwM{G4OkDPxE1?NUjw[XRkW0GQR1XS
SJRH30NV3YZoM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2TKT2lEPTB;MD6zNlA2OiEQvF2=NI\wO5JUSU6JRWK=
COR-L105Mn7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLxTWM2OD1yLkOyNlE5KM7:TR?=MkO0V2FPT0WU
IM-9NXHTZlBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M165XmlEPTB;MD6zN|AzOSEQvF2=NWXCXWh3W0GQR1XS
TE-12NGDidWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmCwTWM2OD1yLkOzN|E4KM7:TR?=NInGTpNUSU6JRWK=
KG-1MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLnSI83UUN3ME2wMlM{PDN{IN88US=>NYKyRlBYW0GQR1XS
U251MkTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\ITWM2OD1yLkOzOFU3KM7:TR?=MVXTRW5ITVJ?
EFO-27M3G1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELCeZBKSzVyPUCuN|M6PTFizszNM{PKR3NCVkeHUh?=
EW-24NEPh[25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTBwM{O5PFQh|ryPMYfTRW5ITVJ?
SF295MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPRTWM2OD1yLkOzPVk6KM7:TR?=MVzTRW5ITVJ?
MC-IXCMnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTBwM{S1JO69VQ>?MnXOV2FPT0WU
NCI-H2405MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH3ncWdKSzVyPUCuN|Q4OzJizszNMl7QV2FPT0WU
NCI-H2009NH7VNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLj[3FKSzVyPUCuN|Q4OzlizszNMX7TRW5ITVJ?
LB1047-RCCNH\UT2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3jtcGlEPTB;MD6zOVgyPSEQvF2=MX\TRW5ITVJ?
KNS-81-FDNVi4cHBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHzDN2lKSzVyPUCuN|Y3PjdizszNMlzQV2FPT0WU
HOP-92NXi5eYNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWnJR|UxRTBwM{[4N{DPxE1?M4XIPHNCVkeHUh?=
L-428NYHq[W9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVHKV45vUUN3ME2wMlM4ODF4IN88US=>MXrTRW5ITVJ?
C3AMnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXn4UnlUUUN3ME2wMlM4Ozd7IN88US=>NH3OU|dUSU6JRWK=
NCI-H1792NIHkXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7udFRRUUN3ME2wMlM4PjV3IN88US=>MV;TRW5ITVJ?
HuH-7NHXWeYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2f6PWlEPTB;MD6zO|kyKM7:TR?=M4DqOHNCVkeHUh?=
AGSMYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXfJR|UxRTBwM{i2N|gh|ryPM2XKe3NCVkeHUh?=
HT-1197NX\SSnh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWrJR|UxRTBwM{m0OkDPxE1?NWnKbYxFW0GQR1XS
CGTH-W-1NEfscXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn\mTWM2OD1yLkO5PVE{KM7:TR?=MkHwV2FPT0WU
KNS-42MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIr1cHJKSzVyPUCuOFAxPDVizszNMUDTRW5ITVJ?
HuO-3N1MmCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M37vb2lEPTB;MD60NFA2PSEQvF2=M13DWnNCVkeHUh?=
VMRC-RCZNHjEbHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrIXJZKSzVyPUCuOFA{ODNizszNMonSV2FPT0WU
SW954M{\3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTmTWM2OD1yLkSwN|M2KM7:TR?=M4mwTHNCVkeHUh?=
MES-SANU[xT4xNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlPxTWM2OD1yLkSwOVA2KM7:TR?=M4rUV3NCVkeHUh?=
Ca-SkiNYe5NGF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4nWdmlEPTB;MD60NFUzPCEQvF2=MoLnV2FPT0WU
SW13NIO4RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7HTWM2OD1yLkSwOlI3KM7:TR?=NVjOVoJRW0GQR1XS
NCI-H1437M2rpRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXvUN4JYUUN3ME2wMlQxQDB3IN88US=>M2fjTHNCVkeHUh?=
U-118-MGNYjhU3pqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4HmOmlEPTB;MD60NFkxPCEQvF2=M1X4UXNCVkeHUh?=
NCI-H1734Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTBwNEKwNVMh|ryPMYTTRW5ITVJ?
HDLM-2NGDz[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\zfmlEPTB;MD60NlA{OyEQvF2=NFzSTnNUSU6JRWK=
AU565NGTYNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXOTWM2OD1yLkSyOFY5KM7:TR?=NHriR45USU6JRWK=
FADUM1z0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXM[I5KSzVyPUCuOFI3PDlizszNNEX1VYdUSU6JRWK=
OS-RC-2NXvtWYhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTBwNEOwPFMh|ryPNXjoSIpRW0GQR1XS
CAMA-1MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml21TWM2OD1yLkSzOlI3KM7:TR?=NUm5dXVlW0GQR1XS
MONO-MAC-6MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXm[4s5UUN3ME2wMlQ{QDR7IN88US=>M3rlcHNCVkeHUh?=
LB831-BLCM13HRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPW[WpKSzVyPUCuOFQ{PzFizszNMWHTRW5ITVJ?
SW982NHK2O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rFUGlEPTB;MD60OFUzQCEQvF2=M37mV3NCVkeHUh?=
SCC-3NF\WToJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWXJR|UxRTBwNES1O|kh|ryPMX\TRW5ITVJ?
C32MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFPuc2VKSzVyPUCuOFUzOjlizszNMmLaV2FPT0WU
BFTC-909M37yWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTBwNEWyPVkh|ryPMXLTRW5ITVJ?
MEG-01Ml\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnjyTWM2OD1yLkS1N|c{KM7:TR?=MnW5V2FPT0WU
M14MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXPJR|UxRTBwNEW5O|kh|ryPNIPBeHRUSU6JRWK=
MPP-89NFT4[lJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUC5WJV6UUN3ME2wMlQ3OjV4IN88US=>M4ewS3NCVkeHUh?=
HCC1937NEjGO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4LJW2lEPTB;MD60OlM5PCEQvF2=NV3reYRwW0GQR1XS
SW837NX;ydYU1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1rPXGlEPTB;MD60OlczOiEQvF2=NWT2cVBTW0GQR1XS
DU-145NU\VNFdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfGTWM2OD1yLkS2O|I6KM7:TR?=NHjndZBUSU6JRWK=
LB996-RCCM1LSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvpPXdKSzVyPUCuOFcxPTRizszNMXfTRW5ITVJ?
C8166NHzrVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTBwNEe0JO69VQ>?MVLTRW5ITVJ?
MOLT-4M1\BfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1\FRWlEPTB;MD60O|c{PCEQvF2=NUHzWplWW0GQR1XS
DMS-53MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MofDTWM2OD1yLkS3PFA6KM7:TR?=NHPifYNUSU6JRWK=
TE-5MkfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFL0WndKSzVyPUCuOFg{ODVizszNNYnCcWNFW0GQR1XS
KYSE-520NUXpfJJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHS0[VhKSzVyPUCuOFg{PDNizszNNGjGeo5USU6JRWK=
Detroit562MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7hPJlKSzVyPUCuOFg5PiEQvF2=NFntbIpUSU6JRWK=
SIMAMmP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWPu[FZWUUN3ME2wMlQ6PDF5IN88US=>Ml7BV2FPT0WU
NCI-H1651Moq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2H5SGlEPTB;MD60PVY4KM7:TR?=NH\vbGlUSU6JRWK=
HCC1599Mk[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2nqR2lEPTB;MD60PVk2PSEQvF2=MlPrV2FPT0WU
ABC-1NX;DRXF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTBwNUC0PVYh|ryPNGDCb5JUSU6JRWK=
CAL-33MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3OwUmlEPTB;MD61NFg1PCEQvF2=NWXCTlBnW0GQR1XS
OPM-2M4PjXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlfETWM2OD1yLkWwPVM4KM7:TR?=MV3TRW5ITVJ?
RPMI-7951NYfqeo5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWPJR|UxRTBwNUC5OVch|ryPNVnxcG02W0GQR1XS
HT-1080NGnybGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXPYSVJ1UUN3ME2wMlUyOTF7IN88US=>MYTTRW5ITVJ?
LC4-1MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVHJR|UxRTBwNUG0NFMh|ryPM2TidHNCVkeHUh?=
OVCAR-3NVO1cph{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LQO2lEPTB;MD61NVU4KM7:TR?=Mn70V2FPT0WU
CAPAN-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTBwNUKyPFgh|ryPNIL5b25USU6JRWK=
SK-OV-3NYr2fnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jmd2lEPTB;MD61NlQ{PCEQvF2=M4Lnb3NCVkeHUh?=
HuP-T3M2H1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWDJR|UxRTBwNUK4Nlch|ryPM{m0V3NCVkeHUh?=
NCI-H838MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4jwVWlEPTB;MD61Nlg1QSEQvF2=NFjLOpZUSU6JRWK=
K5MmjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkDjTWM2OD1yLkWzNlAyKM7:TR?=M2H6eHNCVkeHUh?=
CAL-72NIjrVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XvfGlEPTB;MD61N|M5PyEQvF2=NVu1WI5PW0GQR1XS
NH-12MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{OwbmlEPTB;MD61N|k2QSEQvF2=NXTYUHd5W0GQR1XS
SNB75NWT2W29DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPUfFhYUUN3ME2wMlU2PzNizszNNHTXNYpUSU6JRWK=
BPH-1Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PETGlEPTB;MD61OlM1PCEQvF2=NYT0W5VZW0GQR1XS
NOMO-1NFq1T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTBwNU[zO|Ih|ryPNWm2fXJJW0GQR1XS
G-402NUDEdFl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjxTWM2OD1yLkW2OFk6KM7:TR?=Mm\aV2FPT0WU
NCI-H2052Mn64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1juOWlEPTB;MD61Olc1OSEQvF2=M1TuR3NCVkeHUh?=
RCM-1M37JWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUPJR|UxRTBwNUexOlYh|ryPM2nDW3NCVkeHUh?=
COR-L279M2rjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlH2TWM2OD1yLkW3NVg2KM7:TR?=MofmV2FPT0WU
A253Mni3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYHJR|UxRTBwNUe1NlUh|ryPNYC5UmtUW0GQR1XS
SK-MM-2MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTBwNUe2O|kh|ryPM3nVOXNCVkeHUh?=
NCI-H1703MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrrfm5JUUN3ME2wMlU6PDJ5IN88US=>NXTnTWtqW0GQR1XS
UACC-257NVvKNYlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkLiTWM2OD1yLkW5OFg4KM7:TR?=NWGwbnplW0GQR1XS
KALS-1M4T1PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTBwNkCwNVEh|ryPMoHKV2FPT0WU
ES5MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1jTfmlEPTB;MD62NFQ5KM7:TR?=MlzzV2FPT0WU
MHH-CALL-2M4ix[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfWRoJKSzVyPUCuOlA5QDhizszNMnPsV2FPT0WU
ChaGo-K-1NUHmNYs{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDndW1[UUN3ME2wMlYyOjJ7IN88US=>M{fyNXNCVkeHUh?=
TGBC1TKBM4TVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFTLVFhKSzVyPUCuOlE6QCEQvF2=MnvZV2FPT0WU
KU-19-19MkexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfTOmdKSzVyPUCuOlQ2QDZizszNM2XnNnNCVkeHUh?=
COLO-684NXP6bG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXjNO3ZbUUN3ME2wMlY2PjFzIN88US=>NFfKcG9USU6JRWK=
LS-1034Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjCSGpKSzVyPUCuOlU5OTlizszNNHmxc4ZUSU6JRWK=
RT-112NGq5bZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGjEZnFKSzVyPUCuOlY2QDdizszNNVm2WpgxW0GQR1XS
Capan-2NIXicHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfPTWM2OD1yLk[2OlIzKM7:TR?=MoH1V2FPT0WU
HSC-4NYTLXJV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnraTWM2OD1yLk[2Olk5KM7:TR?=MljFV2FPT0WU
COLO-824NUj0T3VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlvjTWM2OD1yLk[3PFI{KM7:TR?=NXfWVZRyW0GQR1XS
NCI-H2170M{PrdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HrZmlEPTB;MD62PFI2QCEQvF2=MUfTRW5ITVJ?
GDM-1NGTKN4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmD5TWM2OD1yLk[4OFk1KM7:TR?=MU\TRW5ITVJ?
KP-4NV;YXFVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUe0OHIzUUN3ME2wMlY6PTd|IN88US=>Mk\1V2FPT0WU
VA-ES-BJNUDW[IlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnHUTWM2OD1yLk[5PVg3KM7:TR?=MmKzV2FPT0WU
KM-H2NGDHNmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7LTWM2OD1yLkewNFkyKM7:TR?=MmG3V2FPT0WU
HHMnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlj4TWM2OD1yLkewOlYzKM7:TR?=MkXxV2FPT0WU
DK-MGM2\jeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH7pfpBKSzVyPUCuO|ExOTZizszNM3jyWnNCVkeHUh?=
VM-CUB-1MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmPRTWM2OD1yLkexNlU6KM7:TR?=Mo\QV2FPT0WU
COLO-829MnPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWTHToJ4UUN3ME2wMlcyQTh3IN88US=>M3TLfnNCVkeHUh?=
OMC-1MljwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTBwN{KxNFQh|ryPMUXTRW5ITVJ?
NB12MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DtcmlEPTB;MD63NlUxPCEQvF2=M3GwfHNCVkeHUh?=
NCI-H28M{D5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXoSHlKSzVyPUCuO|QxQDNizszNNHvpdJBUSU6JRWK=
A673NE\WPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHzNI94UUN3ME2wMlc2OTd5IN88US=>MXzTRW5ITVJ?
LB2241-RCCMmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVOyVWRXUUN3ME2wMlc3ODh5IN88US=>MknhV2FPT0WU
CCRF-CEMNFnKc5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXWbGlwUUN3ME2wMlc4ODV{IN88US=>NHrKbXlUSU6JRWK=
NCI-H510AMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXLJR|UxRTBwN{exPFYh|ryPMUDTRW5ITVJ?
SW48NYPRO2RzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHZdZF6UUN3ME2wMlc4OzN|IN88US=>MX;TRW5ITVJ?
NCI-H2081M1LOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MonuTWM2OD1yLke4NVQ4KM7:TR?=NULPe2Q6W0GQR1XS
RMG-INXXuNpRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWH3U2ZEUUN3ME2wMlc5OjF{IN88US=>MmjVV2FPT0WU
LU-99ANYXBd3liT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTBwN{i0NVMh|ryPNF\SVHVUSU6JRWK=
KP-N-YSMWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYradXIyUUN3ME2wMlc5QTJzIN88US=>NHfVRmpUSU6JRWK=
MDA-MB-231MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2rSemlEPTB;MD64NFE{OSEQvF2=MkLHV2FPT0WU
U031MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETZSY1KSzVyPUCuPFE1OjNizszNMlXtV2FPT0WU
EVSA-TMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37HfWlEPTB;MD64NVY4OiEQvF2=MnTXV2FPT0WU
MDA-MB-157NFTxdoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTBwOEKyO|Eh|ryPNXL5R4F1W0GQR1XS
EHEBMXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\jNoxKSzVyPUCuPFIzPzZizszNNGjUNWxUSU6JRWK=
KINGS-1MnjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYfSUHFwUUN3ME2wMlgzPTV3IN88US=>NGTMZ3lUSU6JRWK=
23132-87MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo[xTWM2OD1yLkiyPFQ{KM7:TR?=Ml:wV2FPT0WU
EFO-21MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUnJR|UxRTBwOESwPFkh|ryPNEXLdmZUSU6JRWK=
DOKMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXj6[oFmUUN3ME2wMlg1QCEQvF2=MYTTRW5ITVJ?
NCI-H2171NVqxV5pkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\F[WlEPTB;MD64OFk3KM7:TR?=M1XzS3NCVkeHUh?=
NCI-SNU-5MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MljXTWM2OD1yLki1OVch|ryPNVzkNY1vW0GQR1XS
SK-N-DZNFjJOW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXsSItyUUN3ME2wMlg2QTR|IN88US=>M{PiWHNCVkeHUh?=
SNU-C2BM4[weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmXWTWM2OD1yLki2PFAyKM7:TR?=MVnTRW5ITVJ?
CP66-MELM1\tTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHz6fIxKSzVyPUCuPFcyOSEQvF2=MnHLV2FPT0WU
SN12CMkPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVvJR|UxRTBwOEi2N|ch|ryPNULJdZRyW0GQR1XS
A172NHnIWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV6wSppoUUN3ME2wMlg5Pjl6IN88US=>M4rVNXNCVkeHUh?=
NCI-H2347MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoC2TWM2OD1yLki4O|U{KM7:TR?=MknvV2FPT0WU
NCI-H2228MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlPiTWM2OD1yLki5N|M6KM7:TR?=NUW1foRMW0GQR1XS
SNU-387MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm\3TWM2OD1yLkmwNlY1KM7:TR?=NYPwdFN2W0GQR1XS
SK-MEL-24M3q1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnGNoJQUUN3ME2wMlkyOzR2IN88US=>M37Y[nNCVkeHUh?=
MDA-MB-468NWX1VHl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1zFe2lEPTB;MD65NVc{KM7:TR?=NUe5eYZsW0GQR1XS
NCI-H1694M1W4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVTKd3IzUUN3ME2wMlkyQDd4IN88US=>NGXHW2NUSU6JRWK=
CCF-STTG1NELUdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLZTWM2OD1yLkmyOlM4KM7:TR?=Mnz4V2FPT0WU
K052MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH;5eY9KSzVyPUCuPVQxPDdizszNMWfTRW5ITVJ?
NCI-H446NUXxO21tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mme5TWM2OD1yLkm1NFEh|ryPNH7PfXdUSU6JRWK=
MFE-280MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3u3ZmlEPTB;MD65OlI6OSEQvF2=MUnTRW5ITVJ?
KU812MnjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PrRWlEPTB;MD65PVM5QSEQvF2=MlLYV2FPT0WU
MDA-MB-361MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnWN|lKSzVyPUCuPVk4PzdizszNMljCV2FPT0WU
RajiNUfGeZROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTFwMEKyOlch|ryPNEfpVZBUSU6JRWK=
TE-6NVjHcFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLGUmRKSzVyPUGuNFM2PjZizszNNFXRb2FUSU6JRWK=
CAL-148M1\YUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXXGbZRSUUN3ME2xMlA1PDR|IN88US=>NXzPV4tUW0GQR1XS
NCI-H1963M4HoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTFwMES1OVMh|ryPM{nNbXNCVkeHUh?=
SK-N-ASMoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX;4e2V[UUN3ME2xMlA1Pjh3IN88US=>MmDDV2FPT0WU
RERF-LC-MSMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoW4TWM2OD1zLkC2N|Q6KM7:TR?=M2fzbHNCVkeHUh?=
BENNWrSPHF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUPMOXR3UUN3ME2xMlA4OTN5IN88US=>MofIV2FPT0WU
CAS-1MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NE\3Z5pKSzVyPUGuNFkyOjNizszNNUHRUVZIW0GQR1XS
SW780MmjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTFwMEmxPFEh|ryPNVzY[pZ6W0GQR1XS
LU-65NYDy[GZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo\NTWM2OD1zLkC5OFEh|ryPMUDTRW5ITVJ?
D-283MEDMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jLcmlEPTB;MT6xNlI4OiEQvF2=NGrnT4dUSU6JRWK=
HCC2157MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYDlbWloUUN3ME2xMlE{PjR{IN88US=>NH3xVZNUSU6JRWK=
RCC10RGBMofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXzEdFQzUUN3ME2xMlE1ODB4IN88US=>MXnTRW5ITVJ?
PLC-PRF-5M3PVemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUDJR|UxRTFwMUWyNlkh|ryPMkPXV2FPT0WU
H4MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PMSWlEPTB;MT6xOVQ{QSEQvF2=MV;TRW5ITVJ?
TURMVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Moi5TWM2OD1zLkG1O|UzKM7:TR?=MV;TRW5ITVJ?
NCI-H2141Mof5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrFSpNKSzVyPUGuNVg6PDZizszNMWDTRW5ITVJ?
PFSK-1MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXTJR|UxRTFwMkC1N|Ih|ryPM1fmbXNCVkeHUh?=
SK-MEL-28MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvyTWM2OD1zLkKzNlIyKM7:TR?=MoC4V2FPT0WU
SCC-9MnK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWT2UVJtUUN3ME2xMlI{PjZ3IN88US=>Mmn4V2FPT0WU
T47DNHH5fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rX[mlEPTB;MT6yN|Y6PiEQvF2=M1P3V3NCVkeHUh?=
TCCSUPNITKSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfqTWM2OD1zLkK1NFI6KM7:TR?=MofIV2FPT0WU
SU-DHL-1NEX6V2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXYW|JKSzVyPUGuNlUyOThizszNM1;te3NCVkeHUh?=
HL-60M333bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTFwMkW1PFgh|ryPMULTRW5ITVJ?
NCI-H1436NVrGWWhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2SwSGlEPTB;MT6yOlE1QSEQvF2=M{PCUXNCVkeHUh?=
DMS-114MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFnHO2xKSzVyPUGuNlY3OzJizszNNIrOWWxUSU6JRWK=
BOKUM{jFOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjWNVVWUUN3ME2xMlI5ODl3IN88US=>M2\0PHNCVkeHUh?=
MS-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrUdYZ6UUN3ME2xMlI6ODZ7IN88US=>M2XY[XNCVkeHUh?=
NCI-H661NVK0e3dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7ZTWM2OD1zLkOwOFc5KM7:TR?=M4HzbnNCVkeHUh?=
HT-3MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX7JR|UxRTFwM{C1Nlkh|ryPNITPNo5USU6JRWK=
CAL-54M2fEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoXKTWM2OD1zLkOwO|I2KM7:TR?=Mk\LV2FPT0WU
SW1463MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnXNWtwUUN3ME2xMlMyQDd{IN88US=>M4HafnNCVkeHUh?=
COLO-668MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwM{OwOVYh|ryPMmTHV2FPT0WU
PANC-08-13NVnTWJFIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXPycI9DUUN3ME2xMlM{QDB|IN88US=>MYDTRW5ITVJ?
BB49-HNCNUjPfG9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{GyOGlEPTB;MT6zOFAyKM7:TR?=NFHFUolUSU6JRWK=
M059JNFL5SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfkTWM2OD1zLkO1PFMzKM7:TR?=M1zRSnNCVkeHUh?=
NCCITNUXsOWprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlHpTWM2OD1zLkO3PVg5KM7:TR?=MlvUV2FPT0WU
LN-405MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4S4cWlEPTB;MT6zPVI3PCEQvF2=NEXo[2xUSU6JRWK=
UMC-11NUDlfXdzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3P1V2lEPTB;MT6zPVk6PiEQvF2=MlnnV2FPT0WU
NB5MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTFwNEGyNlch|ryPM3HjcXNCVkeHUh?=
TE-441-TMlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFfo[WlKSzVyPUGuOFI5OTdizszNM2\wRnNCVkeHUh?=
ME-180NEDh[IZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTFwNESzPVIh|ryPMnvBV2FPT0WU
HCC70MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3qxcGlEPTB;MT60OlA6PiEQvF2=M1HI[XNCVkeHUh?=
no-10M4\1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGT6fmpKSzVyPUGuOFYyQDFizszNNY\wSZM6W0GQR1XS
JEG-3NWnLZm57T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIDNR5RKSzVyPUGuOVAyOzJizszNNH\afXBUSU6JRWK=
no-11M1:0O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4HxWmlEPTB;MT61NFg5OiEQvF2=MVrTRW5ITVJ?
CHP-126NWflcIk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYPhZmc3UUN3ME2xMlU3PjlzIN88US=>M4X4OHNCVkeHUh?=
EGI-1NInVU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLmTWM2OD1zLkW4NFI2KM7:TR?=MlP3V2FPT0WU
D-392MGNILYbIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHLXNpdKSzVyPUGuOVk3OyEQvF2=MVLTRW5ITVJ?
RT4MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInq[VRKSzVyPUGuOVk3OzdizszNNWfkXZY{W0GQR1XS
A204M4jxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;YTWM2OD1zLkW5PFAyKM7:TR?=NF\2OHhUSU6JRWK=
NCI-H1304M{TWS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWD1OHVjUUN3ME2xMlY{PTlzIN88US=>NUnafFE1W0GQR1XS
BeckerMVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHX1VJhKSzVyPUGuOlQzPDFizszNNH;ScVJUSU6JRWK=
OE19NWTuVnpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NW\HT5Z6UUN3ME2xMlY2PTF6IN88US=>NUHMc5BZW0GQR1XS
EKVXNUnlZ|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTFwNkW2NVgh|ryPM4LkR3NCVkeHUh?=
KLENIi5Wm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTFwNkW3NVQh|ryPMXLTRW5ITVJ?
K-562NXLu[ZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnWS4ZGUUN3ME2xMlY4ODN5IN88US=>NIntdZBUSU6JRWK=
MDA-MB-175-VIIMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUXJR|UxRTFwNki5PVch|ryPM33pbXNCVkeHUh?=
NCI-H716M3n3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUXXOZZ7UUN3ME2xMlY6OzB2IN88US=>MojRV2FPT0WU
Caov-3NFHrS4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vKdGlEPTB;MT62PVQyOyEQvF2=NEjsWmpUSU6JRWK=
HCC1187M3[4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW[1N|hEUUN3ME2xMlcxPTR3IN88US=>M3XseXNCVkeHUh?=
CAKI-1M2K0T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTFwN{KyPVIh|ryPNFr6cVhUSU6JRWK=
MOLT-16M3L0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVjp[otuUUN3ME2xMlc{OzB5IN88US=>NXrzNGk1W0GQR1XS
PC-3NVTzeoZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYXJR|UxRTFwN{WwPEDPxE1?MV3TRW5ITVJ?
DV-90NVrHWWF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTFwN{W1PFUh|ryPM{[xfnNCVkeHUh?=
RXF393NXT4S3NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjtVI9VUUN3ME2xMlc4Ojl2IN88US=>NUGweIVGW0GQR1XS
SK-NEP-1NWDheIl6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX3CbGw2UUN3ME2xMlgzOzN7IN88US=>NYr1WVk{W0GQR1XS
HCC1419M1i3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[3TnVKSzVyPUGuPFI3QTJizszNNX7NW2RMW0GQR1XS
BV-173MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV;U[lZ[UUN3ME2xMlgzQTl3IN88US=>M{jOOnNCVkeHUh?=
MKN7NVnZbGhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2nXfWlEPTB;MT64PVIzKM7:TR?=M33JOXNCVkeHUh?=
LAN-6M2DDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTFwOEm1OVMh|ryPMmrRV2FPT0WU
Mo-TNHLKSYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVrJR|UxRTFwOUCwN|kh|ryPMnfrV2FPT0WU
HCC1395MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2fEVmlEPTB;MT65Nlg3OyEQvF2=M{nWNHNCVkeHUh?=
HC-1M{P5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{TzW2lEPTB;MT65N|Q4KM7:TR?=NEDzUY5USU6JRWK=
HPAF-IIMXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFX3NIhKSzVyPUGuPVQ1OThizszNM3TMV3NCVkeHUh?=
CPC-NM{npWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3zUWGlEPTB;MT65PFAxOiEQvF2=MV\TRW5ITVJ?
MKN45NIS1UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXS1fGZUUUN3ME2xMlk6OTF7IN88US=>NH7wc41USU6JRWK=
NCI-H1693NFG1UpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mlf4TWM2OD1{LkCwOFM{KM7:TR?=MVPTRW5ITVJ?
SHP-77M2POdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{f5S2lEPTB;Mj6wNFU{OyEQvF2=M1fKNXNCVkeHUh?=
NCI-H1522MoDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJwMEG3NlQh|ryPNYruNot{W0GQR1XS
SW1573NEjMNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;aR5Z3UUN3ME2yMlAzOiEQvF2=NVHuTHN4W0GQR1XS
DBTRG-05MGM4Dle2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDEflE1UUN3ME2yMlA3ODh5IN88US=>MkPoV2FPT0WU
SCC-4Mny2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlfqTWM2OD1{LkG0N|Eh|ryPMlvxV2FPT0WU
DMS-153NUHmVJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIHtOpNKSzVyPUKuNVY3PjhizszNNVPVNG5{W0GQR1XS
MDA-MB-415MmPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjhTWM2OD1{LkG3OVIh|ryPMWXTRW5ITVJ?
NCI-H2126MmG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGXnbolKSzVyPUKuNlI5QDhizszNMmewV2FPT0WU
MDA-MB-453M3SxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTJwMkOzNkDPxE1?NELp[mJUSU6JRWK=
U-87-MGNVnSPGlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXW4ZWJXUUN3ME2yMlI5PTl{IN88US=>MoTyV2FPT0WU
LNCaP-Clone-FGCM4XJXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmrrTWM2OD1{LkOwNVAzKM7:TR?=M1fPVnNCVkeHUh?=
NCI-H1581MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTDTWM2OD1{LkOyNVA2KM7:TR?=MnrLV2FPT0WU
BC-3NEjWXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvZTmQ4UUN3ME2yMlM3PTB7IN88US=>MV\TRW5ITVJ?
HCC38NV7ZSIdOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moj3TWM2OD1{LkO4OFQ4KM7:TR?=M1jKd3NCVkeHUh?=
HCC2218MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3HtN2lEPTB;Mj60NFgxQSEQvF2=NU[4WG5tW0GQR1XS
RO82-W-1NY\l[nVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7LTWM2OD1{LkSxNlUh|ryPMUjTRW5ITVJ?
C2BBe1NHLXPXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTJwNEG1O|gh|ryPMnPoV2FPT0WU
LAMA-84NHLmN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkK3TWM2OD1{LkW3N|Y5KM7:TR?=NGLEV3VUSU6JRWK=
GMS-10M2m5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGSwN3lKSzVyPUKuOVc3OTFizszNNGKwVHlUSU6JRWK=
GCTNWi5R|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXmTWM2OD1{LkW4Olk1KM7:TR?=M3n2fHNCVkeHUh?=
SK-CO-1NX\WOmN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLjfXpGUUN3ME2yMlYyPjZizszNNUS0fIR3W0GQR1XS
NCI-H526NFvLWG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXTTWM2OD1{Lk[zOFUh|ryPMXfTRW5ITVJ?
SW1088NVvETW9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4G3e2lEPTB;Mj63O|g{QSEQvF2=M{fvUHNCVkeHUh?=
HT55NHXXdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTJwN{i2PVUh|ryPMYnTRW5ITVJ?
NB10NUXnUVRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3v6fGlEPTB;Mj64NVc1QCEQvF2=NVvYPJU{W0GQR1XS
UACC-893MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJwOEW3OFkh|ryPNXPWPWUzW0GQR1XS
NCI-H1618NGDDPZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NI\se4RKSzVyPUKuPFgyPTNizszNMXrTRW5ITVJ?
NCI-H1092MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrydoZKUUN3ME2zMlA4QDF{IN88US=>MUfTRW5ITVJ?
SBC-1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnTZTWM2OD1|LkC4OVU{KM7:TR?=NWHuUY1HW0GQR1XS
NCI-H1623MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTNwMEmzOEDPxE1?M2rIcHNCVkeHUh?=
SiHaNYKyUJo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PydGlEPTB;Mz6xNVk4PyEQvF2=NVS3emQ6W0GQR1XS
D-263MGMWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHHWU2dKSzVyPUOuNVQ4QDhizszNNGfDZ2JUSU6JRWK=
NCI-H1573Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTNwMUm2OFEh|ryPNGHlfGZUSU6JRWK=
NCI-H82MnP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHTINW5KSzVyPUOuN|Q1OzlizszNMXnTRW5ITVJ?
NCI-H2196NFvSRWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFLySI9KSzVyPUOuN|UxODhizszNNHvGW5lUSU6JRWK=
MFM-223MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{myWWlEPTB;Mz6zO|M2OSEQvF2=MonRV2FPT0WU
COLO-678MmDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYjNO|lTUUN3ME2zMlM5OTh4IN88US=>NVPvbmxoW0GQR1XS
EW-3NYLkOnZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWfwRVlKUUN3ME2zMlQxQTVizszNNXq5VHhCW0GQR1XS
MHH-NB-11M4\Zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrHfZlKSzVyPUOuOFQxPjlizszNM{jJdXNCVkeHUh?=
EM-2NH3XblVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXnQOHpqUUN3ME2zMlY{QThizszNMnzWV2FPT0WU
FTC-133NGTVb3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV;NboZQUUN3ME2zMlY2PDV6IN88US=>MWfTRW5ITVJ?
NCI-H209MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUfmS5JLUUN3ME2zMlY4PjV|IN88US=>MXzTRW5ITVJ?
TGBC24TKBMo\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fMWGlEPTB;Mz62PFM2PSEQvF2=NHizeIFUSU6JRWK=
LC-1FNHeyZXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIT6dmNKSzVyPUOuO|E4PjRizszNMkW5V2FPT0WU
C-4-IIMnjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3S5e2lEPTB;Mz63OVY1OyEQvF2=M{\yOnNCVkeHUh?=
NCI-H1650MmHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTNwN{i0OVUh|ryPNIHK[FNUSU6JRWK=
JVM-2NVG0NIN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fLRmlEPTB;Mz65N|Y{QSEQvF2=NXPo[5RMW0GQR1XS
CaR-1M2P3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MofOTWM2OD1|Lkm3OlE4KM7:TR?=NYnpRVlmW0GQR1XS
MDA-MB-134-VIMl\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTRwMEK5OVIh|ryPM1HHd3NCVkeHUh?=
NCI-H719NGDP[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWTJR|UxRTRwMUWzPFgh|ryPMWDTRW5ITVJ?
GOTONWnhNG06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTRwMkm3NFUh|ryPMofpV2FPT0WU
NCI-N87MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M32xZWlEPTB;ND6zPFgzOSEQvF2=MmLsV2FPT0WU
NB6MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mk\3TWM2OD12LkSyOVA6KM7:TR?=MXrTRW5ITVJ?
DSH1NGLVN5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWLJR|UxRTRwNEexNVYh|ryPM1jBPXNCVkeHUh?=
BT-20NE\Oe5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWO2UGlKUUN3ME20MlQ6ODB{IN88US=>NU\FcZdlW0GQR1XS
NCI-H1882NWDIU5JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEL1WYxKSzVyPUSuOVA2PyEQvF2=MWjTRW5ITVJ?
WM-115NX7Ueog2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTRwNUC4PFEh|ryPNGrNVI1USU6JRWK=
SKG-IIIaNVfKVo5OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmn2TWM2OD12Lk[3O|ch|ryPNW[4V2ZsW0GQR1XS
NCI-H69MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWf1bHVyUUN3ME20MlcxOjd3IN88US=>MW\TRW5ITVJ?
MSTO-211HMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUHTOpdxUUN3ME20Mlg{PTZ3IN88US=>Ml61V2FPT0WU
MewoM3HmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUjWU2pPUUN3ME20Mlk3OzF|IN88US=>NYS2U3dEW0GQR1XS
GI-ME-NM3vBOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2nNS2lEPTB;NT6wNFUxQSEQvF2=MVXTRW5ITVJ?
T98GMmP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M17OemlEPTB;NT6wOlUxQCEQvF2=NHHJd2dUSU6JRWK=
ECC4MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NED6cFlKSzVyPUWuNFk{PzJizszNMUHTRW5ITVJ?
EW-11MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnmTWM2OD13LkG4NFk6KM7:TR?=M1TsTHNCVkeHUh?=
COLO-800M2fBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWS5OIRQUUN3ME21MlE6OzR7IN88US=>M1;TUXNCVkeHUh?=
NCI-H1755NGLvOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV3lOZlQUUN3ME21MlI{ODJ5IN88US=>MmW1V2FPT0WU
KMS-12-PENF;VPGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XURmlEPTB;NT6zOVA5PSEQvF2=MWTTRW5ITVJ?
HCC1954M{PmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWXsVll3UUN3ME21Mlg2QTdzIN88US=>NV33[FdwW0GQR1XS
NCI-H187MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnibWhKSzVyPUWuPVI6QDlizszNMUHTRW5ITVJ?
LU-165NFP6bVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHO[VJKSzVyPUWuPVkxODJizszNM2TqTHNCVkeHUh?=
YAPCNF3kU|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPqTWM2OD13Lkm5NFY5KM7:TR?=MXHTRW5ITVJ?
LU-139NIPHOoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTZwMEizOlgh|ryPM1TF[XNCVkeHUh?=
D-502MGMnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTZwM{KwOFch|ryPMoqwV2FPT0WU
IST-SL1M1[3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17hcGlEPTB;Nj61N|k1QCEQvF2=MUTTRW5ITVJ?
DG-75MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXtbnJKSzVyPU[uPFg4QDZizszNMYnTRW5ITVJ?
NCI-H1155M3nCZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGH6VnhKSzVyPU[uPVU2QDFizszNMofIV2FPT0WU
EFE-184NF3NW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVvsc|dXUUN3ME23MlMyPjl3IN88US=>MmTBV2FPT0WU
AsPC-1M1jFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDiUVBKSzVyPUeuOFg5ODdizszNNGHuPFBUSU6JRWK=
SW948NFnmZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGqxSGJKSzVyPUeuOVg{QTVizszNNHHWT|BUSU6JRWK=
NCI-H524M1rR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1iz[GlEPTB;OT61PFYzQCEQvF2=NVHzSVRRW0GQR1XS
KOSC-2NEnCb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{nzb2lEPTB;OT62Nlg{PCEQvF2=NXX0WW5kW0GQR1XS
T-24MkPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXHJR|UxRTlwOUS0NVUh|ryPNFvxZ3dUSU6JRWK=
NCI-H748MmX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVTJR|UxRTFyLk[zPVch|ryPM3vISnNCVkeHUh?=
NCI-H23NG\T[mRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M37Ue2lEPTB;MUCuOlQ1OiEQvF2=NWH4fZlTW0GQR1XS
UACC-812NV62TJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfadnRLUUN3ME2xNU44OTdizszNM3P3Z3NCVkeHUh?=
SCLC-21HMmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUPJR|UxRTF{LkG1OVEh|ryPM{fwZXNCVkeHUh?=
NCI-SNU-16NYXDepRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrkepVKSzVyPUGzMlEzPThizszNNEmxNlVUSU6JRWK=
HD-MY-ZMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmHJTWM2OD1zND62N|Y{KM7:TR?=NIW0ZldUSU6JRWK=
SK-N-FIMWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHWTWM2OD1zND64PVEzKM7:TR?=NU\IXGJwW0GQR1XS
LB647-SCLCMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M13rOmlEPTB;MUWuO|E6PSEQvF2=M{PTOXNCVkeHUh?=
NCI-H345NWLyNYdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\TSWNOUUN3ME2xO{4{PDNizszNMmLPV2FPT0WU
NCI-H1563NXjUVIdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTF6Lke2NFEh|ryPMWXTRW5ITVJ?
RLM1GwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWfJR|UxRTJzLkK2OVYh|ryPM1m2V3NCVkeHUh?=
KY821MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PycWlEPTB;MkKuNFU2OyEQvF2=MXfTRW5ITVJ?
JVM-3NInkUHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1TyNGlEPTB;MkWuNFQyOyEQvF2=NFHRZ4tUSU6JRWK=
NCI-H1793MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUTJR|UxRTJ6LkW0PVkh|ryPNH;BdWZUSU6JRWK=
LU-134-ANVz1TYtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4TQbGlEPTB;M{CuNlA{PyEQvF2=NFX5T2dUSU6JRWK=
NCI-H1395NYLFbIxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTtdXd{UUN3ME2zNk4zPDNzIN88US=>MWfTRW5ITVJ?
NCI-H1993NH7MUpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTN{LkiyNVgh|ryPMWTTRW5ITVJ?
P31-FUJMkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzsPWhKSzVyPUOzMlQ5QTlizszNNH3lVXVUSU6JRWK=
LS-513NF6ySHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYCzNoFXUUN3ME2zOU45QDd7IN88US=>M3;jVnNCVkeHUh?=
SK-MEL-1M4jtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q1d2lEPTB;NECuN|Q6QSEQvF2=NYnJeHB4W0GQR1XS
SW684NIC1WZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVTNeZdWUUN3ME20N{46PjZzIN88US=>MmDmV2FPT0WU
COR-L88NUPn[|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTRTWM2OD12ND6wOlY2KM7:TR?=M4TF[nNCVkeHUh?=
NCI-H889NFfReoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2PR[GlEPTB;NEWuNFA5PyEQvF2=NEf4UnpUSU6JRWK=
TALL-1NV3uNmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzSfZBKSzVyPUS2MlEyQTlizszNMo\tV2FPT0WU
KARPAS-299M{jrU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4rXOWlEPTB;NEeuNVk6OyEQvF2=NF[4cJFUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Protocol(Only for Reference)

Kinase Assay: [1]

Bcl-2 Binding affinity calculation A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.

Cell Assay: [2]

Cell lines Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
Concentrations ~10 μM
Incubation Time 48-72 hours
Method Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.

Animal Study: [1]

Animal Models Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
Formulation Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
Dosages 0.0313, 0.25, 0.5 and 2 mg/kg
Administration Administered intravenously (tail vein) once a day

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Nguyen M, et al. Proc Natl Acad Sci, 2007, 104(49), 19512-191517.

[2] Trudel S, et al. Blood, 2009, 113(2), 299-305.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-01-10)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymp  ...more Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|  ...more Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor, Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2

view more

Chemical Information

Download Obatoclax Mesylate (GX15-070) SDF
Molecular Weight (MW) 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 83 mg/mL (200.73 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (Z)-2-(5-((3,5-dimethyl-1H-pyrrol-2-yl)methylene)-4-methoxy-5H-pyrrol-2-yl)-1H-indole mesylate

Customer Product Validation (9)


Click to enlarge
Rating
Source Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunohistochemical staining
Cell Lines Mice
Concentrations 3 mg/kg
Incubation Time 3 weeks
Results Tumors from 3 mice in each group were analyzed with H&E and immunohistochemical staining. Interestingly, H&E staining revealed substantially increased necrosis in the tumors for GX15-070 treated groups compared to the vehicle control group, especially for the combination (AZD2281 and GX15-070) group.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Electron microscopic morphology
Cell Lines T1682 cells
Concentrations 100, 1000 nM
Incubation Time 1, 6, 48 h
Results Gx15-070 treatment of TET cells leads to both growth inhibition and cell death. Gx15-070 induces autophagy-dependent necroptosis in acute lymphoblastic leukemia cells, it's performed electron microscopy (EM) in TET cells, which demonstrated changes in mitochondrial structure as early signs of autophagy after 1 h Gx15-070 treatment. After 6 h treatment, cytoplasmic vacuolization and mitochondrial swelling with early signs of necroptotic cell death were evident. Intriguingly, cytoplasmic vacuolization, late-stage necroptotic or autophagic cell death were the main features 48 h after Gx15-070 (1 uM) treatment.

Click to enlarge
Rating
Source Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Western blot
Cell Lines T1682 cells
Concentrations 100, 250, 500, 1000 nM
Incubation Time 6 h
Results Gx15-070 induced a progressive reduction of AKT Ser473 and Thr308 phosphorylation and a reduction of p-RPS6 phosphorylation, suggesting inhibition of mTOR pathway, in line with previous reports. Moreover, Gx15-070 induced phosphorylation of AMPKα, a Ser/Thr kinase normally activated when ATP level is reduced.AMPK phosphorylation and LC3B cleavage appeared within 1 h after Gx15-070 treatment.

Click to enlarge
Rating
Source Cell death dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Viability assay
Cell Lines BM3.3 CD8 T cells
Concentrations 0.1-10uM
Incubation Time
Results T-cell activation induced resistance to Bcl-2 inhibition by ABT-737 (no binding of A1 and Mcl-1) and by Antimycin A (no binding of A1 only), but had no impact on the proapoptotic potency of the pan-Bcl-2 inhibitor obatoclax.

Click to enlarge
Rating
Source Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Immunostaining
Cell Lines HUH6 cells
Concentrations 0.1, 0.3 uM
Incubation Time 24 h
Results In HUH6 cells mitochondria with an intact membrane potential were observed in the JC-1 staining in both, control and TNF-a treated cultures (C, D). The number of reddish points indicating active mitochondria decreased when the HUH6 cells were treated with obatoclax and decreased even further when the treatment was performed in combination with TNF-a, which reflects the breakdown of mitochondrial membranes decreased aggregation of JC-1. This was concentration dependent (E-H).

Click to enlarge
Rating
Source BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell proliferation assays
Cell Lines SET-2 cells
Concentrations 1-10000 nM
Incubation Time 72 h
Results Incubation of SET-2 cells with sub-optimal concentrations of the pan-Bcl-2 family protein inhibitor obatoclax in cell proliferation assays lowered the GI 50 of NVP-BSK805 by 3 to 4 fold.

Click to enlarge
Rating
Source Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Clonogenic survival assay
Cell Lines MEF cells
Concentrations 0-300 ng/mL
Incubation Time 24 h
Results

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Hoechst staining
Cell Lines MDB-MA-231 cells
Concentrations 1 μM
Incubation Time
Results

Click to enlarge
Rating
Source Obatoclax Mesylate (GX15-070) purchased from Selleck
Method Cell Viability/Western Blot
Cell Lines Nalm-6 ABT-R cells
Concentrations 5-10 uM
Incubation Time 18 h
Results Nalm-6 ABT-R cells were sensitive to obatoclax; however, Nalm-6 cells were equally sensitive (IC50: 10 umol/L). Reh parental cells (IC50: 5umol/L) were also more sensitive to obatoclax compared with ABT-R cells, as measured by trypan blue exclusion. Mcl-1 protein levels were downregulated following obatoclax treatment. NOXA levels also increased, however these changes did not correlate with cell death.

Product Use Citation (24)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Bcl-2 Products

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

  • ABT-737

    ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

  • UMI-77

    UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.

  • TW-37

    TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.

  • Sabutoclax

    Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

  • AT101

    AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Recently Viewed Items

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us